- Home
- RGNX vs ZIMV Comparison
RGNX vs ZIMV Comparison
Compare RGNX & ZIMV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- ZIMV
- Stock Information
- Founded
- RGNX 2008
- ZIMV 2021
- Country
- RGNX United States
- ZIMV United States
- Employees
- RGNX N/A
- ZIMV N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RGNX Health Care
- ZIMV Health Care
- Exchange
- RGNX Nasdaq
- ZIMV Nasdaq
- Market Cap
- RGNX 451.1M
- ZIMV 532.3M
- IPO Year
- RGNX 2015
- ZIMV N/A
- Fundamental
- Price
- RGNX $9.26
- ZIMV $18.89
- Analyst Decision
- RGNX Strong Buy
- ZIMV Hold
- Analyst Count
- RGNX 8
- ZIMV 3
- Target Price
- RGNX $28.50
- ZIMV $14.50
- AVG Volume (30 Days)
- RGNX 528.4K
- ZIMV 652.0K
- Earning Date
- RGNX 11-05-2025
- ZIMV 10-29-2025
- Dividend Yield
- RGNX N/A
- ZIMV N/A
- EPS Growth
- RGNX N/A
- ZIMV N/A
- EPS
- RGNX N/A
- ZIMV N/A
- Revenue
- RGNX $155,782,000.00
- ZIMV $443,402,000.00
- Revenue This Year
- RGNX $203.27
- ZIMV $2.49
- Revenue Next Year
- RGNX $0.58
- ZIMV $1.26
- P/E Ratio
- RGNX N/A
- ZIMV N/A
- Revenue Growth
- RGNX 74.95
- ZIMV N/A
- 52 Week Low
- RGNX $5.04
- ZIMV $8.15
- 52 Week High
- RGNX $13.48
- ZIMV $19.01
- Technical
- Relative Strength Index (RSI)
- RGNX 52.58
- ZIMV 75.30
- Support Level
- RGNX $8.82
- ZIMV $18.85
- Resistance Level
- RGNX $10.08
- ZIMV $18.93
- Average True Range (ATR)
- RGNX 0.55
- ZIMV 0.06
- MACD
- RGNX -0.03
- ZIMV -0.17
- Stochastic Oscillator
- RGNX 42.66
- ZIMV 29.41
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.